Roferon-a, 3miu (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 56 | ベーチェット病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-005390-36-GB (EUCTR) | 17/02/2016 | 31/12/2015 | BIO BEHCET'S TRIAL | Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment. - BIO BEHÇET’S | Behcets Disease MedDRA version: 18.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Remicade Product Name: Remicade Product Code: 3400935113276 INN or Proposed INN: infliximab Trade Name: Roferon-A, 3miu Product Name: Roferon-A 3miu Product Code: 8699505952864 INN or Proposed INN: alpha interferon Trade Name: Roferon-A, 4.5miu Product Name: Roferon-A, 4.5miu Product Code: J1081 INN or Proposed INN: alpha interferon Trade Name: Roferon-A, 6miu Product Name: Roferon-A, 6miu Product Code: 2387066 INN or Proposed INN: alpha interferon | The University of Liverpool | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 3 | United Kingdom |